Allist Pharmaceuticals, Inc.

This study is comparing a new daily pill called firmonertinib against standard platinum-based chemotherapy for people with advanced non-small cell lung cancer (NSCLC) who have specific genetic changes (EGFR PACC or L861Q mutations). The goal is to see if the pill is more effectiv…

This study is testing an experimental drug called Glecirasib for people with advanced pancreatic cancer and other solid tumors that have a specific genetic change called KRAS G12C. The trial is for patients whose cancer has continued to grow despite previous standard treatments. …

This large, international Phase 3 trial is testing if a new drug combination works better than the current standard treatment for a specific type of advanced lung cancer that has spread to the brain. It will compare furmonertinib (a newer targeted drug) given with standard chemot…

This is the first study in people testing a new oral medication called AST2303 for advanced non-small cell lung cancer. The main goals are to find a safe dose, understand how the body processes the drug, and look for early signs that it might help shrink tumors. The study will en…